BioCryst Pharmaceuticals Inc
NASDAQ:BCRX

Watchlist Manager
BioCryst Pharmaceuticals Inc Logo
BioCryst Pharmaceuticals Inc
NASDAQ:BCRX
Watchlist
Price: 7.57 USD 2.44% Market Closed
Market Cap: 1.6B USD
Have any thoughts about
BioCryst Pharmaceuticals Inc?
Write Note

Gross Margin
BioCryst Pharmaceuticals Inc

98.1%
Current
98%
Average
63.9%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
98.1%
=
Gross Profit
404.6m
/
Revenue
412.6m

Gross Margin Across Competitors

Country US
Market Cap 1.6B USD
Gross Margin
98%
Country FR
Market Cap 6T USD
Gross Margin
0%
Country US
Market Cap 310.3B USD
Gross Margin
67%
Country US
Market Cap 141.6B USD
Gross Margin
60%
Country US
Market Cap 115.3B USD
Gross Margin
78%
Country US
Market Cap 102.4B USD
Gross Margin
86%
Country US
Market Cap 94.1B EUR
Gross Margin
76%
Country AU
Market Cap 134.4B AUD
Gross Margin
52%
Country US
Market Cap 77.3B USD
Gross Margin
87%
Country US
Market Cap 39.3B EUR
Gross Margin
75%
Country NL
Market Cap 35.8B EUR
Gross Margin
89%
No Stocks Found

BioCryst Pharmaceuticals Inc
Glance View

Market Cap
1.6B USD
Industry
Biotechnology

BioCryst Pharmaceuticals Inc., a beacon in the realm of niche biopharmaceutical innovations, has carved its path by focusing on the development of novel oral drugs that address rare and serious medical conditions. Anchored by its expertise in small molecule therapies, BioCryst operates at the intricate intersection of biology and chemistry, designing drugs that intervene in essential biological pathways. Its flagship product, ORLADEYO® (berotralstat), received a significant nod of approval when it was launched as the first oral, once-daily prophylactic treatment for hereditary angioedema (HAE). This rare condition, characterized by recurrent swelling attacks, previously had limited treatment options, often requiring cumbersome and painful injections. The oral nature of ORLADEYO filled a critical unmet need, propelling the company to a lucrative frontier within the pharmaceutical market. Revenue generation for BioCryst is firmly rooted in the licensing and sale of its proprietary drugs. With ORLADEYO, the company has not only achieved a foothold in a specialty pharmaceutical market but also laid a foundation for sustainable financial growth. Through strategic pricing and distribution channels, supported by collaboration with global healthcare partners, BioCryst maximizes its market reach while focusing on adding to its pipeline with promising candidates in various stages of clinical development. Its approach is a careful blend of scientific innovation and business acumen, ensuring that the impacts of their breakthroughs are not only felt in prolonged patient lifespans but also reflected in the company’s bottom line.

BCRX Intrinsic Value
12.3 USD
Undervaluation 38%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
98.1%
=
Gross Profit
404.6m
/
Revenue
412.6m
What is the Gross Margin of BioCryst Pharmaceuticals Inc?

Based on BioCryst Pharmaceuticals Inc's most recent financial statements, the company has Gross Margin of 98.1%.